Redcare Pharmacy Raises 2026 Revenue Guidance Again as German Prescription Business Continues Strong Growth
Redcare Pharmacy N.V. has raised its full-year 2026 revenue guidance for the second time this year, supported by continued strong growth in its prescription business in Germany.
The company said the latest upgrade reflects the ongoing momentum of its Rx business, with preliminary figures showing particularly strong growth during the third quarter and in September. According to the company, German Rx revenue increased by 56% year over year in the third quarter and by 51% in September.
The performance is notable because September was compared with a strong period from the previous year, when the current prescription bonus had been introduced. Despite that challenging comparison base, Redcare Pharmacy continued to report strong prescription revenue momentum.
The company plans to provide the complete financial results for the third quarter of 2026 on October 29, 2026, when it will publish its Interim Statement and host its quarterly conference call.For Redcare Pharmacy, the latest guidance increase reflects the continued development of its prescription business in Germany and the company’s progress in building its digital pharmacy platform.
German Rx Business Drives the Guidance Upgrade
The main factor behind the latest increase in Redcare Pharmacy’s 2026 revenue outlook is the performance of its German prescription business.Prescription revenue, or Rx revenue, in Germany remained strong throughout the third quarter. Preliminary figures indicate that the business grew 56% year over year during the quarter.
The company also reported 51% year-over-year growth in September.September’s performance is particularly significant because the company was facing a high comparison base. During the same period of the previous year, Redcare Pharmacy benefited from the introduction of the current Rx bonus.
Despite that comparison, the company continued to deliver strong growth in German prescription revenue.Based on this performance, Redcare Pharmacy has increased its expectations for full-year German Rx revenue.
The company now expects German Rx revenue to reach between €730 million and €760 million in 2026. This represents expected growth of approximately 45% to 51%.The previous guidance had projected German Rx revenue of between €680 million and €720 million, representing growth of approximately 35% to 43%.
The new forecast therefore represents a meaningful increase in both the expected revenue range and the anticipated growth rate.
Overall 2026 Revenue Growth Outlook Increased
Alongside the stronger German prescription outlook, Redcare Pharmacy has also raised its expectations for total revenue growth.The company now expects total revenue to increase by between 16% and 18% in 2026.Previously, Redcare Pharmacy had guided for total revenue growth of between 15% and 17%.
The revised range reflects the continued contribution of the German Rx business to the company’s overall performance.While the company has increased its total revenue growth expectations, it has maintained its existing guidance for non-Rx growth.Redcare Pharmacy continues to expect non-Rx revenue to grow by between 10% and 12% during 2026.
The company also maintained its adjusted EBITDA margin guidance at between 2.5% and 3.0%.This means the latest guidance update primarily reflects the stronger prescription revenue outlook rather than a change in the company’s profitability target.
Non-Rx Revenue Recovers After a Softer July
While prescription revenue remained strong throughout the third quarter, Redcare Pharmacy said its non-Rx business in Germany experienced a different pattern during the period.Non-Rx revenue refers to products outside the prescription business and represents another important component of Redcare Pharmacy’s operations.
According to the company, non-Rx revenue in Germany was softer in July but rebounded well during August and September.This recovery helped support the company’s overall quarterly performance.The improvement in August and September provides a more balanced picture of the company’s performance across both prescription and non-prescription categories.
The company has maintained its full-year non-Rx growth guidance at 10% to 12%, indicating that it continues to expect steady development in this part of the business.The stronger Rx performance, combined with the recovery in non-Rx revenue toward the end of the quarter, contributed to the company’s decision to increase its overall revenue expectations for the year.
Customer Satisfaction Continues to Improve
Redcare Pharmacy also highlighted customer satisfaction as another important indicator of the performance of its digital prescription business.Olaf Heinrich, CEO of Redcare Pharmacy, said the company’s growth continues to be supported by strong customer satisfaction.
According to Heinrich, the company’s eRx Net Promoter Score, or eRx NPS, increased by six points year over year to reach 80 in August.NPS is commonly used by companies to measure customer satisfaction and willingness to recommend a service.
For Redcare Pharmacy, the continued increase in its eRx NPS provides an additional indicator of customer engagement with its electronic prescription offering.The company believes this customer satisfaction momentum supports the ongoing development of its prescription business in Germany.
Heinrich said the company’s growth is backed by strong customer satisfaction, highlighting the increase in the eRx NPS as part of the company’s recent performance.
What the Updated Guidance Means
The latest guidance update provides a clearer picture of where Redcare Pharmacy expects its 2026 business to finish.The company has now set the following full-year targets:
- Total revenue growth: 16% to 18%, compared with previous guidance of 15% to 17%.
- Non-Rx revenue growth: 10% to 12%, unchanged from the previous guidance.
- German Rx revenue: €730 million to €760 million, compared with previous guidance of €680 million to €720 million.
- German Rx growth: 45% to 51%, compared with the previous expectation of 35% to 43%.
- Adjusted EBITDA margin: 2.5% to 3.0%, unchanged.
These updated figures show that the biggest change is in the company’s expectations for German prescription revenue.The increase in German Rx guidance has also contributed to the upward revision in total revenue growth expectations.
At the same time, Redcare Pharmacy has retained its existing profitability outlook, with adjusted EBITDA margin still expected to remain between 2.5% and 3.0%.
Strong Rx Momentum Remains Central to the Business
Prescription revenue has become an increasingly important part of Redcare Pharmacy’s growth story in Germany.The latest figures show that the company continues to experience strong momentum in the segment.
The 56% year-over-year growth reported for the third quarter and 51% growth reported for September demonstrate the strength of the business based on the company’s preliminary figures.The September performance is particularly relevant because of the comparison with the previous year.
The company noted that the current Rx bonus had been introduced during the prior-year period, creating a high comparison base.Despite that factor, German Rx revenue continued to expand strongly.This performance has given Redcare Pharmacy sufficient confidence to increase its full-year expectations for the second time during 2026.
Operating Leverage Supports EBITDA Margin
Along with the revenue performance, Redcare Pharmacy also highlighted developments in its adjusted EBITDA margin.The company said the adjusted EBITDA margin remained flat quarter over quarter based on preliminary figures.Continued operating leverage supported the margin during the period.
Operating leverage refers to the ability of a company to spread its operating costs across a growing revenue base.As revenue increases, businesses can potentially improve efficiency if costs do not rise at the same pace.For Redcare Pharmacy, the company said continued operating leverage benefited its adjusted EBITDA margin during the third quarter.
Despite the stronger revenue outlook, the company has not changed its full-year adjusted EBITDA margin guidance.The target remains between 2.5% and 3.0%.
Third-Quarter Results Coming on October 29
The figures announced by Redcare Pharmacy are preliminary. The company will provide the complete set of third-quarter financial figures later in October.Redcare Pharmacy is scheduled to publish its Interim Statement for the third quarter of 2026 on October 29, 2026.
The company will also host its quarterly conference call on the same date.The full results will provide additional information about the company’s revenue performance, profitability and development across its different business areas.
Investors and market participants will also have an opportunity to review the detailed performance behind the updated full-year guidance.Until the complete quarterly results are released, the latest figures should be viewed as preliminary information from the company.
A Stronger Outlook for the Full Year
Redcare Pharmacy’s latest announcement represents another increase in its expectations for 2026.The company had already provided its previous guidance, but stronger-than-expected momentum in the German prescription business has prompted another upward revision.
The new total revenue growth target of 16% to 18% reflects the company’s confidence in continuing business momentum through the remainder of the year.The most significant change is the German Rx forecast, which has increased from €680 million to €720 million previously to €730 million to €760 million under the updated outlook.
The company is now expecting German prescription revenue growth of between 45% and 51%, compared with the previous expectation of 35% to 43%.At the same time, the company continues to expect non-Rx growth of 10% to 12% and an adjusted EBITDA margin of 2.5% to 3.0%.
Redcare Pharmacy enters the final part of 2026 with strong momentum in its German prescription business and a higher revenue outlook than it had previously expected.The preliminary third-quarter figures point to continued growth in German Rx revenue, with the segment increasing 56% year over year during the quarter and 51% in September.
The company also reported that German non-Rx revenue recovered during August and September after a softer July.Customer satisfaction remains another area of focus, with the eRx NPS reaching 80 in August, six points higher than the previous year.For Redcare Pharmacy, these developments have supported its decision to raise its full-year 2026 guidance for the second time this year.
The company now expects total revenue growth of 16% to 18%, German Rx revenue of €730 million to €760 million and continued non-Rx growth of 10% to 12%. Its adjusted EBITDA margin target remains unchanged at 2.5% to 3.0%.The next major update will come on October 29, when Redcare Pharmacy publishes its complete third-quarter 2026 results and holds its quarterly conference call.
Until then, the preliminary figures provide an early indication that prescription momentum in Germany continues to be a major driver of Redcare Pharmacy’s business performance and its revised outlook for the full year.
Source link: https://www.redcare-pharmacy.com/
